A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Michael Alan Schwarzschild18 enrolled

Overview

The purpose of this study is to assess the effects of food on the amount of urate in the body after a single oral dose of inosine.

Eighteen (18) eligible healthy male subjects will be randomly assigned to two groups with 9 subjects per group to receive a single oral dose of 1000 mg inosine with or without food on day 1 after an overnight fast. Subjects who receive inosine with food on day 1 will receive a second dose of inosine without food on day 8 after an overnight fast. Subjects who receive inosine without food on day 1 after an overnight fast will receive a second dose of inosine with food on day 8 after an overnight fast. Subjects will be admitted to the clinic before dinner on days 0 and 7, the days before dosing, and will stay in the clinic for 48-h post-dose. During the clinic stay, blood samples will be taken for urate measurements.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

InosineDRUG

Inosine, 1000 mg

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy male subjects between the ages of 18 and 65 years 2. Body-mass index between 18.0 kg/m2 and 32.0 kg/m2 3. If not surgically sterile, willing to refrain from donating sperm and willing to use appropriate birth control when engaging in sexual intercourse for a period of 90 days following the last dose of the study medication 4. Serum urate \< 6.1 mg/dL (approximately 360 μM) at screening 5. Non-smokers for at least 6 months prior to screening 6. Adequate venous access at multiple sites in both arms Exclusion Criteria: 1. History of alcohol or drug dependence in the past 2 years 2. Had 400 mL of whole blood collection within four months or 200 mL of whole blood collection or who had blood component collection within one month of the screening test 3. Used prescription or over-the-counter (OTC) drugs within 14 days prior to screening 4. Used vitamin preparations or supplements (including St. John's Wort and ginseng) within 28 days prior to the screening test 5. Not willing to refrain from alcohol, grapefruit, grapefruit juice or related products, caffeine consumption (including chocolate), and strenuous exercise within 72 h prior to day 1 and through the end of the PK study 6. Treated with an investigational drug within 30 days or 7 half-lives of the investigational drug, whichever is longer, prior to the first dose of study drug 7. Previously received inosine supplement within three months from the screening or subjects who have had any inosine and suffered an adverse reaction due to it 8. Known HIV disease 9. Had a febrile illness within 5 days prior to the first dose of study medication 10. Vaccinated within 30 days prior to the first dose of medication 11. Has gout or a history or suspicion of kidney stones 12. Determined by the investigator or sub-investigator to be unsuitable for participating in the study based on medical conditions

Locations (1)

Covance Clinical Research Unit Inc.

Evansville, Indiana, United States

Outcomes

Primary Outcomes

Cmax: Maximum Observed Serum Urate Concentration

Time frame: -12 to 0 hrs pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs post-dose

AUC (0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Plasma Concentration)

Time frame: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

AUC (0-inf): Area Under the Serum Concentration-time Curve From Time 0 to Infinity

Time frame: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Tmax: Time of Maximum Serum Concentration

Time frame: -12 to 0 hr pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

T1/2: Apparent Terminal Half-life

Time frame: -12 to 0 pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Baseline Corrected Cmax: Baseline Corrected Maximum Serum Concentration

Correction for individual endogenous urate levels was done by subtracting the individual mean endogenous baseline concentration prior to dosing from each post-dose concentration in the profile. The two samples collected at -12 h and 0 h (pre-dose) before the meal were used to measure the mean endogenous baseline concentrations in each dosing period (periods 1 and 2). Negative concentrations were set to zero.

Time frame: -12 to 0 hr pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 hrs post-dose

Baseline Corrected AUC (0-t): Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Time t (Time of Last Quantifiable Serum Concentration)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes